Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 24 Apr 2023
Canada: The Journal of Psychiatric Research recently reported that childhood cat ownership, particularly with rodent-hunting cats,.
Read Full NewsPrograms offering telehealth counseling and nicotine replacement products should be part of routine oncology care, researchers say.
Researchers evaluate minimal residual disease status in 128 adults with relapsed or refractory follicular lymphoma treated with epcoritamab.
A new study explores whether germline profiling could refine the subclassification and prognosis of therapy-related myeloid neoplasms beyond treatment history alone.
1.
Analysis of NRG trial in limited-stage small cell lung cancer suggests QOL benefit with twice- vs. once-daily radiation
2.
A prostate cancer risk prediction algorithm could help target men at highest risk
3.
Off-the-Shelf Drug Matches CAR-T Effects in Refractory Lupus
4.
Hemihedral resection not necessary for neuroendocrine surgery after appendicitis
5.
New PET tracer enables same-day imaging of triple-negative breast and urothelial cancers
1.
Advances in Cancer Detection: From Genetic Risk to Molecular Biomarkers
2.
Emerging Frameworks in Oncology in Clinical Decision-Making
3.
Functional Iron Reserve Screening Before Clinical Deficiency: Clinical Insights and Evidence-Based Strategies
4.
Screening Strategies in Oncology: A Subspecialty Guide to Early Detection and Better Outcomes
5.
The Complications and Treatments of Intraosseous Hemangioma - A Comprehensive Guide
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Further Discussion on A New Perspective
2.
Exploring the Hospitalization Burden in Refractory and Relapsed ALL
3.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part II
4.
The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
5.
Navigating the Complexities of Ph Negative ALL - Part IV
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge